


Claims

1. A compound of formula (I):



or a pharmaceutically acceptable salt thereof,

wherein:

R^1 is selected from the group consisting of F, C_1 - C_4 alkyl, C_1 - C_4 alkoxy, $C(O)R^5$, C_3 - C_8 cycloalkyl, 3-12 membered heterocyclyl and 5-12 membered heteroaryl, where each said C_1 - C_4 alkyl or C_1 - C_4 alkoxy is optionally substituted by one or more R^6 , and each said C_3 - C_8 cycloalkyl, 3-12 membered heterocyclyl or 5-12 membered heteroaryl is optionally substituted by one or more R^7 ;

R^2 is H, F or C_1 - C_4 alkyl;

L is a bond or a C_1 - C_4 alkylene;

R^3 is selected from the group consisting of C_1 - C_4 alkyl, C_1 - C_4 alkoxy, OH, CN, $C(O)R^8$, $COOR^9$, $NR^{10}R^{11}$, OR^{12} , C_3 - C_8 cycloalkyl, 3-12 membered heterocyclyl and 5-12 membered heteroaryl, where each said C_1 - C_4 alkyl or C_1 - C_4 alkoxy is optionally substituted by one or more R^6 , and each said C_3 - C_8 cycloalkyl, 3-12 membered heterocyclyl or 5-12 membered heteroaryl is optionally substituted by one or more R^7 ;

R^4 is H, halo or C_1 - C_4 alkyl, where each said C_1 - C_4 alkyl is optionally substituted by one or more R^6 ;

R^5 is C_1 - C_4 alkyl, where each said C_1 - C_4 alkyl is optionally substituted by one or more R^{14} ;

each R^6 is independently OH, F, CN or C_1 - C_4 alkoxy;

each R^7 is independently C_1 - C_4 alkyl, OH, F, CN, C_1 - C_4 alkoxy, =O, CHO, $C(O)R^{13}$, SO_2R^{13} or 3-6 membered heterocyclyl;

R^8 is C_1 - C_4 alkyl, where each said C_1 - C_4 alkyl is optionally substituted by one or more R^{14} ;

R^9 is H or C_1 - C_4 alkyl, where each said C_1 - C_4 alkyl is optionally substituted by one or more R^{14} ;

R¹⁰ and R¹¹ are independently H or C₁-C₄ alkyl, where each said C₁-C₄ alkyl is optionally substituted by one or more R¹⁴;

R¹² is selected from the group consisting of C₃-C₈ cycloalkyl, 3-12 membered heterocyclyl and 5-12 membered heteroaryl, where each said C₃-C₈ cycloalkyl, 3-12 membered heterocyclyl or 5-12 membered heteroaryl is optionally substituted by one or more R⁷;

each R¹³ is independently C₁-C₄ alkyl, where each said C₁-C₄ alkyl is optionally substituted by one or more R¹⁵;

each R¹⁴ and R¹⁵ is independently OH, F, CN or C₁-C₄ alkoxy; and

X and Z are independently C₁-C₄ alkyl, C₁-C₄ fluoroalkyl, C₁-C₄ alkoxy or C₁-C₄ fluoroalkoxy.

2. The compound or salt of claim 1, wherein R² is H.

3. The compound or salt of claim 1 or 2, wherein R⁴ is Cl, F, Br or CH₃.

4. The compound or salt of claim 1, 2 or 3, wherein X is CH₃, OCH₃ or OCHF₂ and Z is CH₃.

5. The compound or salt any one of claims 1 to 4, wherein R¹ is C₁-C₄ alkoxy optionally substituted by one or more R⁶.


6. The compound or salt of claim 5 wherein said C₁-C₄ alkoxy is OCH₃.

7. The compound or salt of any one of claims 1 to 4, wherein R¹ is C₁-C₄ alkyl optionally substituted by one or more R⁶.

8. The compound or salt of any one of claims 1 to 7, wherein L is a bond and R³ is 3-12 membered heterocyclyl optionally substituted by one or more R⁷.

9. The compound or salt of claim 8, wherein said 3-12 membered heterocyclyl is selected from the group consisting of oxetanyl, tetrahydrofuranyl and tetrahydropyranyl, each optionally substituted by one or more R⁷.

10. A compound of Formula (I-A):



or a pharmaceutically acceptable salt thereof, wherein:

R^1 is C_1 - C_4 alkoxy;

R^2 is H;

L is a bond;

R^3 is 3-12 membered heterocyclyl, optionally substituted by one or more R^7 ;

R^4 is H or Cl;

each R^7 is independently C_1 - C_4 alkyl, OH, F, CN, C_1 - C_4 alkoxy, =O, CHO, $C(O)R^{13}$, SO_2R^{13} or 3-6 membered heterocyclyl;

each R^{13} is independently C_1 - C_4 alkyl, where each said C_1 - C_4 alkyl is optionally substituted by one or more R^{15} ;

each R^{15} is independently OH, F, CN or C_1 - C_4 alkoxy; and

X and Z are independently C_1 - C_4 alkyl, C_1 - C_4 fluoroalkyl, C_1 - C_4 alkoxy or C_1 - C_4 fluoroalkoxy.

11. The compound or salt of claim 10, wherein R^3 is 3-12 membered heterocyclyl selected from the group consisting of oxetanyl, tetrahydrofuranyl and tetrahydropyranyl, each optionally substituted by one or more R^7 .


12. A compound that is 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(*R*)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2*H*)-one, or a pharmaceutically acceptable salt thereof.

13. A compound that is 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(*R*)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2*H*)-one.

14. A compound that is 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2*H*)-one, or a pharmaceutically acceptable salt thereof.

15. A compound that is 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(*S*)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2*H*)-one, or a pharmaceutically acceptable salt thereof.

16. A compound of formula (III):



or a pharmaceutically acceptable salt thereof,
wherein:

R^1 and R^3 are taken together to form a 3-12 membered heterocyclyl optionally substituted by one or more R^7 ;

R^2 is H, F or C_1 - C_4 alkyl;

R^4 is H, halo or C_1 - C_4 alkyl, where each said C_1 - C_4 alkyl is optionally substituted by one or more R^6 ;

each R^6 is independently OH, F, CN or C_1 - C_4 alkoxy;

each R^7 is independently C_1 - C_4 alkyl, OH, F, CN, C_1 - C_4 alkoxy, =O, CHO, $C(O)R^{13}$, SO_2R^{13} or 3-6 membered heterocyclyl;

each R^{13} is independently C_1 - C_4 alkyl, where each said C_1 - C_4 alkyl is optionally substituted by one or more R^{15} ;

each R^{15} is independently OH, F, CN or C_1 - C_4 alkoxy; and

X and Z are independently C_1 - C_4 alkyl, C_1 - C_4 fluoroalkyl, C_1 - C_4 alkoxy or C_1 - C_4 fluoroalkoxy.

17. The compound or salt of claim 16, wherein R^1 and R^3 are taken together to form a 3-12 membered heterocyclyl selected from the group consisting of azetidiny,

pyrrolidinyl, piperidinyl and homopiperidinyl, each optionally substituted by one or more R^7 .

18. The compound or salt of claim 17, wherein R^7 is CHO, $C(O)R^{13}$ or SO_2R^{13} and
5 each R^{13} is independently C_1 - C_4 alkyl optionally substituted by one or more R^{15} .

19. A pharmaceutical composition comprising a compound of any one of claims 1 to 18, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

10

20. A pharmaceutical composition for the treatment of abnormal cell growth, comprising a compound of any one of claims 1 to 18, or a pharmaceutically acceptable salt thereof.

15 21. The pharmaceutical composition of claim 20, wherein the abnormal cell growth is cancer.

22. A compound of any one of claims 1 to 18, or a pharmaceutically acceptable salt thereof, for use in the treatment of abnormal cell growth in a subject.

20

23. A pharmaceutical composition comprising a compound according to any one of claims 1 to 18, or a pharmaceutically acceptable salt thereof used in combination with one or more additional anti-cancer agents.

25 24. The pharmaceutical composition according to any one of claims 19 to 21 further comprising one or more additional anti-cancer agents.